These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584 [TBL] [Abstract][Full Text] [Related]
9. [Myasthenia gravis induced by autoantibodies against MuSK]. Shigemoto K; Konishi T; Ohta M Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361 [TBL] [Abstract][Full Text] [Related]
10. Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy. Skriapa L; Zisimopoulou P; Trakas N; Grapsa E; Tzartos SJ J Neuroimmunol; 2014 Nov; 276(1-2):150-8. PubMed ID: 25262156 [TBL] [Abstract][Full Text] [Related]
11. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Tzartos SJ; Bitzopoulou K; Gavra I; Kordas G; Jacobson L; Kostelidou K; Lagoumintzis G; Lazos O; Poulas K; Sideris S; Sotiriadis A; Trakas N; Zisimopoulou P Ann N Y Acad Sci; 2008; 1132():291-9. PubMed ID: 18567880 [TBL] [Abstract][Full Text] [Related]
12. The auto-antigen repertoire in myasthenia gravis. Vrolix K; Fraussen J; Molenaar PC; Losen M; Somers V; Stinissen P; De Baets MH; Martínez-Martínez P Autoimmunity; 2010 Aug; 43(5-6):380-400. PubMed ID: 20380581 [TBL] [Abstract][Full Text] [Related]
13. Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains. Lazaridis K; Evaggelakou P; Bentenidi E; Sideri A; Grapsa E; Tzartos SJ J Neuroimmunol; 2015 Jan; 278():19-25. PubMed ID: 25595248 [TBL] [Abstract][Full Text] [Related]
14. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Lauriola L; Ranelletti F; Maggiano N; Guerriero M; Punzi C; Marsili F; Bartoccioni E; Evoli A Neurology; 2005 Feb; 64(3):536-8. PubMed ID: 15699390 [TBL] [Abstract][Full Text] [Related]
15. Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis. Trakas N; Zisimopoulou P; Tzartos SJ J Neuroimmunol; 2011 Dec; 240-241():79-86. PubMed ID: 21993075 [TBL] [Abstract][Full Text] [Related]
16. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395 [TBL] [Abstract][Full Text] [Related]
17. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Higuchi O; Hamuro J; Motomura M; Yamanashi Y Ann Neurol; 2011 Feb; 69(2):418-22. PubMed ID: 21387385 [TBL] [Abstract][Full Text] [Related]
18. Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency. Kostelidou K; Trakas N; Tzartos SJ J Neuroimmunol; 2007 Oct; 190(1-2):44-52. PubMed ID: 17764755 [TBL] [Abstract][Full Text] [Related]
19. Myasthenia gravis experimentally induced with muscle-specific kinase. Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854 [TBL] [Abstract][Full Text] [Related]